Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDD vs VAD in Newly Diagnosed Multiple Myeloma
NCT00344422Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2000
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 3 trial of doxorubicin liposomal in multiple myeloma (MM), sponsored by Johnson & Johnson. Started Oct 2000; status: completed.
02
Drugs
doxorubicin liposomal
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00344422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00344422.